Replimune secures $200M non-dilutive debt facility from Hercules Capital

Replimune Group, Inc.

$200M term loan; $30M funded at closing, $30M available by Sep 30, 2023.
Up to $115M available upon clinical/regulatory/commercial milestones; $25M subject to Hercules consent.
Interest: floating cash rate (greater of 7.25% or Prime+1.75% capped at 7.25%) plus 1.50% PIK.
At least 48 months interest-only, extendable to 60 months on milestone achievement; matures Oct 2027.
Proceeds extend cash runway into 2025 ahead of CERPASS/IGNYTE trial catalysts and commercial prep.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.